In a significant development, Eli Lilly announced on Friday the approval of its weight loss drug tirzepatide by Chinese regulators, marking a major milestone in the competition with its Danish counterpart, Novo Nordisk, in the crucial Asian market. The approval comes as a strategic move to tap into China, the world's second-largest economy and home to a significant population struggling with overweight or obesity.
Following Novo Nordisk's approval of its weight loss drug Wegovy in China earlier in June, the competition between the two pharmaceutical giants has escalated, driving up their respective share prices. Eli Lilly's shares rose by 1.6% to $862.39 in midday trading as the news of tirzepatide's approval circulated.
The spokesperson for Eli Lilly remained tight-lipped on specific details regarding the launch date of tirzepatide in China and the volume of doses that would be supplied. Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound, is poised to enter the Asian market alongside its established counterparts.
Both Eli Lilly and Novo Nordisk are diligently working to scale up production capacity to meet the growing demand in the weight-loss market, which is projected to exceed $100 billion globally by 2030. The obesity treatments offered by the two companies fall under the category of GLP-1 agonists, originally designed for diabetes management, and have demonstrated the potential to help patients achieve substantial weight loss of up to 20%.
With the approval of tirzepatide in China, Eli Lilly and Novo Nordisk are poised for a head-to-head competition to capture a significant share of the burgeoning weight-loss market in Asia, setting the stage for an intense rivalry in the race to address the pressing global issue of obesity.